Chime Financial Stock Lands New $129 Million Bet Despite Tepid Post-IPO Performance

Ashton Thomas Private Wealth initiated a new 13F position in Chime Financial (NASDAQ: CHYM), acquiring 5,128,770 shares valued at $129.1 million (3.1% of the fund’s reportable AUM) with shares at $26.22 on January 29. Chime’s trailing twelve‑month revenue is $2.07 billion with a net loss of $984.8 million, but the most recent quarter showed 29% revenue growth to $544 million, 9.1 million active members (+21% YoY) and adjusted EBITDA of $29 million, while management raised full‑year guidance and authorized a $200 million buyback. The stake signals institutional conviction in Chime’s shift from pure growth to operating leverage and positions the fund as a concentrated consumer‑finance exposure alongside its large liquid holdings.

Analysis

Market structure: Ashton Thomas’s $129m, 3.1% stake in CHYM signals a shift of active capital into scaled, interchange-driven fintechs; direct winners are Chime (CHYM), its issuing/partner banks, and card networks (share volumes), while small regional banks that compete for low-balance retail deposits face margin pressure. The move increases concentration risk in consumer-fintech beta vs broad market beta (fund still heavy in AAPL/MSFT/IVV), and marginal demand for CHYM shares/derivatives should tighten liquidity for outsized moves around earnings or buyback windows.

Risk assessment: Key tail risks are regulatory caps on interchange or overdraft/advance products, partner-bank operational failure, and credit deterioration if unemployment rises; each could wipe out current adjusted EBITDA gains. Immediate (days) risk is headline-driven flow; short-term (weeks/months) hinges on guidance and buyback execution; long-term (quarters) depends on sustained ARPU growth (currently $245) and sustained CAC decline. Hidden dependency: Chime’s economics rely on interchange concentration and third-party bank relationships that can change contractually.

Trade implications: Direct long CHYM exposure is rational at current $26.22 if sizing is risk-aware—use phased builds into $22–27 over 2–6 weeks and target a 30–50% upside if EBITDA margins hold. Consider a call-spread (9–15 month) to cap cost and sell short regional-bank exposure (KRE) to express fintech win over deposit-based franchises. Options: buy Jan 2027 LEAP $25C and sell $40C (ratio 1:1) or buy 3-month $22 puts as tail protection ahead of earnings.

Contrarian angles: Consensus focuses on growth-to-operating-leverage narrative but underestimates regulatory and interchange-policy risk; valuation (~4.5x TTM revenue, $9.3bn mkt cap) already prices sustained high ARPU and low CAC. Historical parallels: early profitable card-driven players (Capital One) scaled margins, but many fintech IPOs rerated down after regulatory scrutiny. Unintended consequence: buybacks reduce war chest for product/credit loss buffers, magnifying downside in stress scenarios.

Key Decisions for Investors

• Establish a phased long position in CHYM equal to 1.5–2.5% of portfolio over 2–6 weeks, accumulating between $22–$27; set a tactical stop-loss at a 20% drawdown and a fundamental stop if sequential active-member growth drops below 5% QoQ or adjusted EBITDA turns negative next quarter.
• Implement a defined-risk options trade: buy Jan 2027 CHYM $25 calls and sell Jan 2027 $40 calls (1:1) sized to equal 1% portfolio exposure to cap premium and target 40–60% IRR on move above $40 by Jan 2027.
• Run a relative-value pair: go long CHYM (0.75% portfolio) and short ISE:KRE (0.75% portfolio) to express consumer-fintech share gains vs regional-bank deposit margin compression; rebalance monthly and unwind if CHYM outperforms KRE by >30% in 3 months or underperforms by >15%.
• Hedge downside around near-term catalysts: buy 3-month CHYM $22 puts sized to 25% of long-equivalent notional if implied volatility is <30%; otherwise prefer a cheaper 3–6 month put spread ($20/$15) to protect against regulatory headlines.
• Monitor three trigger metrics over next 30–90 days before increasing exposure: (1) CFPB or Federal Reserve guidance on interchange/advance products; (2) next-quarter ARPU change (target maintain or grow >0% QoQ); (3) execution of $200m buyback (announce repurchases executed >=50% within 6 months).